Meeting
2023 ASCO Quality Care Symposium
Burden of myelosuppression in extensive-stage small-cell lung cancer patients receiving chemotherapy: Retrospective analysis of real-world data from Tennessee Oncology.
Authors
L. Johnetta Blakely
Tennessee Oncology, Nashville, TN
L. Johnetta Blakely, Zheng-Yi Zhou, Marie Louise Edwards, Kirthana Sarathy, Fan Yang, Ashley Roush, Michelle Moore, Huan Huang
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A
Track
Quality, Safety, and Implementation Science,Cost, Value, and Policy,Patient Experience,Survivorship
Sub Track
Symptom Prevention, Assessment, and Management
Citation
JCO Oncol Pract 19, 2023 (suppl 11; abstr 364)
DOI
10.1200/OP.2023.19.11_suppl.364
Abstract #
364
Poster Bd #
F21
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Impact of trilaciclib on multilineage chemotherapy-induced myelosuppression events in patients with extensive-stage small cell lung cancer: Post-hoc analyses of data from randomized clinical trials.
First Author: Jerome H. Goldschmidt
Poster
2021 ASCO Annual Meeting
Real-world evidence of cancer immunotherapy (CIT) combination treatment in first-line (1L) extensive-stage small cell lung cancer (ES-SCLC).
First Author: Eric S. Nadler
Poster
2024 ASCO Annual Meeting
Survival outcomes of patients with extensive-stage small cell lung cancer who received treatment with atezolizumab in combination with carboplatin and etoposide: A propensity score adjusted cohort study.
First Author: Heya Batah
Poster
2023 ASCO Quality Care Symposium
Patient characteristics associated with myelosuppression among patients with extensive-stage small cell lung cancer treated with chemotherapy in the community oncology setting.
First Author: Jerome H. Goldschmidt